📊 RKDA Key Takeaways
Is RKDA a Good Investment? Thesis Analysis
Arcadia Biosciences faces imminent liquidity crisis with $259K cash reserves against $4.7M annual operating burn, providing only 1.3 weeks of operational runway. Despite impressive 2098% revenue growth, the company operates at -48% net margin and -51.5% operating margin, losing $2.3M on $4.9M revenue, indicating a fundamentally unsustainable business model.
Why Buy RKDA? Key Strengths
- Exceptional 2098% year-over-year revenue growth demonstrates significant market traction or business expansion from prior period
- Zero long-term debt eliminates financial leverage risk and restructuring concerns
- Current ratio of 3.09x and quick ratio of 2.50x indicate asset-to-liability positioning superior to cash position alone
RKDA Investment Risks to Consider
- Critical liquidity crisis: $259K cash insufficient for $4.7M annual operating burn (approximately 13 days of runway)
- Operating model fundamentally broken with negative operating cash flow of $4.7M exceeding revenue generation of $4.9M
- Severe unprofitability with -48.1% net margin, -51.5% operating margin, and negative returns on equity (-56.5%) and assets (-35.7%)
Key Metrics to Watch
- Monthly cash burn rate and days of liquid capital remaining - immediate survival metric
- Operating cash flow trajectory - must achieve positive OCF within weeks to avoid insolvency
- Revenue growth sustainability and gross margin - assess whether growth is profitable or accelerating cash depletion
RKDA Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 3.09x current ratio provides a solid financial cushion.
RKDA Profitability Ratios
RKDA vs Energy Sector
How Arcadia Biosciences, Inc. compares to Energy sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is RKDA Overvalued or Undervalued?
Based on fundamental analysis, Arcadia Biosciences, Inc. has mixed fundamental signals relative to the Energy sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
RKDA Balance Sheet & Liquidity
RKDA 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: Arcadia Biosciences, Inc.'s revenue has declined by 37% over the 5-year period, indicating business contraction. The most recent EPS of $-5.17 indicates the company is currently unprofitable.
RKDA Growth Metrics (YoY)
RKDA Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $1.3M | $856.0K | $0.62 |
| Q2 2025 | $1.3M | $1.1M | $0.78 |
| Q1 2025 | $987.0K | -$2.4M | $-1.78 |
| Q3 2024 | $1.3M | -$1.6M | $-1.18 |
| Q2 2024 | $1.3M | $823.0K | $0.61 |
| Q1 2024 | $1.2M | -$2.4M | $-1.78 |
| Q3 2023 | $1.6M | -$2.6M | $-1.89 |
| Q2 2023 | $1.4M | $823.0K | $0.61 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
RKDA Capital Allocation
RKDA SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for Arcadia Biosciences, Inc. (CIK: 0001469443)
📋 Recent SEC Filings
❓ Frequently Asked Questions about RKDA
What is the AI rating for RKDA?
Arcadia Biosciences, Inc. (RKDA) has an AI rating of STRONG SELL with 95% confidence, based on fundamental analysis of SEC EDGAR filings.
What are RKDA's key strengths?
Claude: Exceptional 2098% year-over-year revenue growth demonstrates significant market traction or business expansion from prior period. Zero long-term debt eliminates financial leverage risk and restructuring concerns.
What are the risks of investing in RKDA?
Claude: Critical liquidity crisis: $259K cash insufficient for $4.7M annual operating burn (approximately 13 days of runway). Operating model fundamentally broken with negative operating cash flow of $4.7M exceeding revenue generation of $4.9M.
What is RKDA's revenue and growth?
Arcadia Biosciences, Inc. reported revenue of $4.9M.
Does RKDA pay dividends?
Arcadia Biosciences, Inc. does not currently pay dividends.
Where can I find RKDA SEC filings?
Official SEC filings for Arcadia Biosciences, Inc. (CIK: 0001469443) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is RKDA's EPS?
Arcadia Biosciences, Inc. has a diluted EPS of $-1.71.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is RKDA a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Arcadia Biosciences, Inc. has a STRONG SELL rating with 95% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is RKDA stock overvalued or undervalued?
Valuation metrics for RKDA: ROE of -56.5% (sector avg: 14%), net margin of -48.1% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy RKDA stock in 2026?
Our dual AI analysis gives Arcadia Biosciences, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is RKDA's free cash flow?
Arcadia Biosciences, Inc.'s operating cash flow is $-4.7M, with capital expenditures of $0.0. FCF margin is -97.6%.
How does RKDA compare to other Energy stocks?
Vs Energy sector averages: Net margin -48.1% (avg: 12%), ROE -56.5% (avg: 14%), current ratio 3.09 (avg: 1.3).